Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients
Janssen Cilag Gm Alexandra Nisipeanu Jennifer Mcintyre Prinzj Ponesimod Janssen Cilag International None Of The Janssen Pharmaceutical Companies
Source: finanznachrichten.de